37 results about "Calcium signaling" patented technology

A statistical and functional correlation strategy to identify changes in cellular pathways specifically linked to impaired cognitive function with aging. Analyses using the strategy identified multiple groups of genes expressed in the hippocampi of mammals, where the genes were expressed at different levels for several ages. The aging changes in expression began before mid-life. Many of the genes were involved in specific neuronal and glial pathways with previously unrecognized relationships to aging and/or cognitive decline. The processes identified by the strategy suggest a new hypothesis of brain aging in which initially decreased neuronal activity and/or oxidative metabolism trigger separate but parallel genomic cascades in neurons and glia. In neurons, the cascade results in elevations in calcium signaling and reductions of immediate early gene signaling, biosynthesis, synaptogenesis and neurite remodeling. In contrast, glia undergo increased lipid metabolism and mediate a cycle of demyelination and remyelination that induces antigen presentation, inflammation, oxidative stress and extracellular restructuring. These identified genes and the proteins they encode can be used as novel biomarkers of brain aging and as targets for developing treatment methods against age-related cognitive decline, Alzheimer's Disease and Parkinson's Disease.

In certain aspects, the invention relates to use of PKD2 agonists, such as triptolide and triptolide derivatives, to regulate calcium release. In other aspects, the invention relates to use of PKD2 agonists to treat or aid in the treatment of any condition in which a calcium channel, such as the gene product of PKD 1 and/or PKD2, is mutated; calcium signaling is abnormal; or both, such as polycystic kidney disease.

The present invention relates to compositions and methods useful for detecting and/or measuring, e.g., intracellular signaling in vivo. More particularly, compositions and methods are provided, which include transgenic animals, that are useful in mapping and examining, e.g., calcium fluctuations in vivo between and within populations of cells in real time. Methods for screening for candidate compounds that effect, e.g., intracellular calcium signaling are also provided.

The present invention provides reagents and methods for identifying inhibitors of the L-type Ca²⁺ channel β₃ protein, which has been demonstrated to be involved in calcium signaling, insulin secretion, and glucose homeostasis. The invention also provides therapeutics and methods for treating a subject with one or more of diabetes, insulin resistance, impaired insulin secretion, and impaired glucose homeostasis, involving the use of inhibitors of an L-type Ca²⁺ channel β₃ subunit to provide a benefit to the subject.

IgA receptors, including a polymeric immunoglobulin receptor (pIgR) and a FcαR, have been found on smooth muscle cells, synovial fibroblast cells and on both synovial and endothelial cells in synovial tissues from patients with arthritis. Incubation of smooth muscle cells or tissue with pIgA increases cytosolic calcium and alters the contractile state. Incubation of synovial cells with IgA modulates the inflammatory responses of these cells. The invention relates to methods of modulating calcium signalling and/or contractility of mesenchymal cells, as well as modulating (preferably inhibiting) the inflammatory responses of mesenchymal cells, methods of treating inflammatory conditions (such as asthma and arthritis), methods of drug delivery to mesenchymal cells and methods of detecting conditions associated with IgA receptors on mesenchymal cells.

The invention relates to the technical field of genetic engineering, and particularly relates to a peanut glutamyl t-RNA reductase, and further relates to applications of the peanut glutamyl t-RNA reductase in regulating the expression of chlorophyll and calmodulin. The peanut glutamyl t-RNA reductase has the beneficial effects that the functions of the peanut glutamyl t-RNA reductass are identified, namely, the peanut glutamyl t-RNA reductase has the actions of regulating the expression of chlorophyll and calmodulin, thus clearing the action relationship of reductase and calcium signals and establishing a theory basis for later research.

The present invention relates to use of miR-18b for prevention, treatment, or diagnosis of muscle diseases or neuromuscular diseases, and specifically it was confirmed that, in a muscle disease by gene mutations model, gene mutations reduce miR-18b expression, cause dysregulation of miR-18b signaling pathways, and thus induce calcium signaling, cell differentiation inhibition, and apoptosis. Therefore, miR-18b of the present invention may be used as a target factor for diagnosing and treating muscle diseases caused by gene mutations such as ALS and DMD.

The present invention describes a calcium-binding myristoylated protein with homology to calcineurin B which interacts preferentially with presenilin 2 protein. Also, the present invention relates to methods that alter protein-protein interaction of the calcium-binding myristoylated protein with presenilin 2 thereby reducing deleterious effects of the protein-protein interaction, such as apoptosis. The present invention further relates to introducing and expressing a mutant presenilin 2 protein or mutant calcium-binding myristoylated protein to modulate cell functions relating to calcium signaling and apoptosis.

The present invention features methods that allow for diagnosing a risk for a patient or subject developing an Autism Spectrum Disorder, for identifying potentially therapeutic anti-ASD agents, and methods for treatment monitoring as specified in the independent claims.

The invention relates to the field of biological medicine, and in particular, relates to an application of an FRT cell strain in preparation of a preparation or a kit for screening a Chrm3 regulator.FRT cells endogenously express Chrm3 in mRNA and protein levels; an FRT cell model capable of stably co-expressing ANO1 and YFP-H148Q/I152L is successfully constructed; the cell model can sensitivelydetect the intracellular calcium concentration, the slope value of fluorescence change and the concentration of the Chrm3 regulator form a dose-dependent relationship, and the cell model can be used for screening the Chrm3 regulator; the Z' factor value of the model is 0.678, and the requirement of high-throughput screening is met. The cell model realizes high-throughput screening of the Chrm3 regulator by sensitively detecting a calcium signal, and can also be applied to screening of other GPCR targets related to the calcium ion signal.